Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8420259 | 1.00 | POLB (0.45) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL8421466 | 1.00 | POLB (0.45) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL8420261 | 1.00 | POLB (0.45) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL1701604 | 0.83 | POLB (0.49) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL15438887 | 0.83 | POLB (0.49) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL7342618 | 0.83 | POLB (0.45) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL15447586 | 0.83 | POLB (0.49) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL7289985 | 0.83 | POLB (0.49) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL8406208 | 0.83 | POLB (0.49) | POLBMEN1KMT2AKDM4EEBP | |
| SCHEMBL23182281 | 0.82 | POLB (0.35) | POLBMEN1KMT2AKDM4EEBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0585682-B1 | Process for the preparation of 2,6-dimethylmorpholine from N-(2-hydroxypropyl)-2,6-dimethylmorpholine | BASF AG (DE) | 1999-10-06 | — | — | EP | claimed |
| EP-0585682-A2 | Process for the preparation of 2,6-dimethylmorpholine from N-(2-hydroxypropyl)-2,6-dimethylmorpholine | BASF Aktiengesellschaft (DE) | 1994-03-09 | — | — | EP | claimed |
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| WO-2012065057-A2 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-8044206-B2 | Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl | ASTELLAS PHARMA INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044206-B2 | Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl | ASTELLAS PHARMA INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| EP-0585682-B1 | Process for the preparation of 2,6-dimethylmorpholine from N-(2-hydroxypropyl)-2,6-dimethylmorpholine | BASF AG (DE) | 1999-10-06 | — | — | EP | disclosed |
| US-5436335-A | Catalytic dealkylation using group Ib, IIb and group VIII metals | BASF AKTIENGESELLSCHAFT (DE) | 1995-07-25 | — | — | US | disclosed |
| EP-0585682-A2 | Process for the preparation of 2,6-dimethylmorpholine from N-(2-hydroxypropyl)-2,6-dimethylmorpholine | BASF Aktiengesellschaft (DE) | 1994-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | SCN1B, CACNA1B, SCN2A | POLB 4207/4885MEN1 3647/4885KMT2A 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.